WallStSmart

Southern Copper Corporation (SCCO)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Southern Copper Corporation generates 12% more annual revenue ($13.42B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 32.3%. VRTX appears more attractively valued with a PEG of 2.19. VRTX earns a higher WallStSmart Score of 66/100 (B-).

SCCO

Strong Buy

65

out of 100

Grade: B-

Growth: 9.3Profit: 10.0Value: 6.0Quality: 7.8
Piotroski: 5/9

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SCCOUndervalued (+13.4%)

Margin of Safety

+13.4%

Fair Value

$243.36

Current Price

$165.49

$77.87 discount

UndervaluedFair: $243.36Overvalued
VRTXUndervalued (+36.5%)

Margin of Safety

+36.5%

Fair Value

$716.04

Current Price

$454.97

$261.07 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SCCO6 strengths · Avg: 9.8/10
Return on EquityProfitability
42.7%10/10

Every $100 of equity generates 43 in profit

Profit MarginProfitability
32.3%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
54.5%10/10

Strong operational efficiency at 54.5%

Revenue GrowthGrowth
39.0%10/10

Revenue surging 39.0% year-over-year

EPS GrowthGrowth
60.4%10/10

Earnings expanding 60.4% YoY

Market CapQuality
$131.83B9/10

Large-cap with strong market position

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

SCCO3 concerns · Avg: 3.3/10
P/E RatioValuation
30.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
12.4x4/10

Trading at 12.4x book value

PEG RatioValuation
5.412/10

Expensive relative to growth rate

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : SCCO

The strongest argument for SCCO centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 54.5%. Revenue growth of 39.0% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : SCCO

The primary concerns for SCCO are P/E Ratio, Price/Book, PEG Ratio.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

SCCO profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.

SCCO carries more volatility with a beta of 1.08 — expect wider price swings.

SCCO is growing revenue faster at 39.0% — sustainability is the question.

SCCO generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 65/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Southern Copper Corporation

BASIC MATERIALS · COPPER · USA

Southern Copper Corporation is engaged in the extraction, exploration, smelting and refining of copper and other minerals in Peru, Mexico, Argentina, Ecuador and Chile.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?